Ares reports $150.6 million Q2 net income
Ares Management (NYSE:ARES) announced its second-quarter 2026 financial results, posting a GAAP net income attributable to the company of $150.6 million, or $0.49 per share.
Ares Management (NYSE:ARES) announced its second-quarter 2026 financial results, posting a GAAP net income attributable to the company of $150.6 million, or $0.49 per share.
Linde (NASDAQ:LIN) reported second-quarter 2026 sales of $9.3 billion, up 9% year over year, with adjusted earnings per share increasing as the company reported higher operating performance.
Apple (NASDAQ:AAPL) shares fell 7.3% before the market open on Friday after the company warned that supply constraints could limit growth, raising concerns about future product availability.
Magna (NYSE:MGA) reported second-quarter 2026 sales of $11 billion, up 3% year over year, outperforming a 2% decline in global light vehicle production.
Portland General Electric (NYSE:POR) reported second-quarter 2026 GAAP net income of $68 million, or $0.59 per diluted share, compared with $62 million, or $0.56 per share, in the prior-year quarter.
Compañía de Minas Buenaventura (NYSE:BVN) reported second-quarter 2026 net income of $260.6 million, compared with $98.2 million in the prior-year quarter, as gold production increased during the period.
Kyivstar Group (NASDAQ:KYIV) reported second-quarter 2026 revenue of $339 million, up 19.3% year over year, as digital services growth contributed to higher group performance.
VEON (NASDAQ:VEON) reported second-quarter 2026 revenue of $1.27 billion, up 17% year over year, as digital services growth supported overall performance.
Datroway (datopotamab deruxtecan), developed by Daiichi Sankyo and AstraZeneca (NYSE:AZN), received European Union approval as a monotherapy treatment for adults with unresectable or metastatic triple negative breast cancer who are not candidates for PD-1/PD-L1 inhibitor therapy.
Telegram founder Pavel Durov denied allegations linking the messaging platform to terrorism after comments from Russian authorities.
GET YOUR GRAFA EDGE NOW
We'll switch on a 30-day Edge trial as a welcome gift
Got a second for a cookie? 🍪Essential cookies keep Grafa running smoothly. A few optional ones help us see what's working so we can make it better. You're in control — change your mind any time. Cookie policy · Privacy policy